TGF-β has been considered a master of immunosuppression of TME, but inhibiting TGF-β signaling with the targeted therapy with galunisertib was unsuccessful in a phase 2 clinical trial in patients with GBM [44]. This evidence concerns the gene TGFB1 and glioblastoma.